digitalcommons.nyls.edu
Faculty Scholarship

Articles & Chapters

2015

Stem Cell Patents after the America Invents Act
Jacob S. Sherkow
New York Law School

Christopher Scott

Follow this and additional works at: http://digitalcommons.nyls.edu/fac_articles_chapters
Part of the Intellectual Property Law Commons, Medical Jurisprudence Commons, and the
Science and Technology Law Commons
Recommended Citation
16 Cell Stem Cell 461-464 (May 7, 2015)

This Article is brought to you for free and open access by the Faculty Scholarship at DigitalCommons@NYLS. It has been accepted for inclusion in
Articles & Chapters by an authorized administrator of DigitalCommons@NYLS.

Cell Stem Cell

Forum
Stem Cell Patents after the America Invents Act
Jacob S. Sherkow1,* and Christopher Thomas Scott2,*
1Innovation

Center for Law and Technology, New York Law School, New York, NY 10013, USA
Cells in Society, Center for Biomedical Ethics, Stanford School of Medicine, Stanford University, Stanford, CA 94305, USA
*Correspondence: jacob.sherkow@nyls.edu (J.S.S.), cscott@stanford.edu (C.T.S.)
http://dx.doi.org/10.1016/j.stem.2015.04.015
2Program on Stem

Under the newly passed Leahy-Smith America Invents Act (AIA), the U.S. Patent and Trademark Office may
hear new challenges to stem cell patents. Here, we explore how the new law affects challenges to stem cell
patents, focusing on two recent cases, and discuss the future of stem cell patent disputes.
Introduction
Stem-cell-related patents have long been
at the center of controversy. Religious
groups, patent lawyers, and even other
scientists have criticized the process of
claiming ownership over the most fundamental of biological building blocks
(Golden, 2010). Nonetheless, true legal
challenges to the validity or enforceability
of many stem cell patents remain rare and
are often limited to a narrow subset of current licensees (Plomer et al., 2008). Newly
developed administrative procedures at
the U.S. Patent and Trademark Office
(PTO), however, may change this calculus. Under the Leahy-Smith America Invents Act (AIA), which has been in effect
since 2012, the PTO may now hear
several types of new challenges to both
pending patent applications and already
issued patents. These new administrative
procedures may be filed by anyone,
regardless of the person’s legal interest
in the patent. This shift may open the
door to more frequent—and aggressive—patent challenges by disparate
stakeholders against stem cell patents.
Interestingly, two recent failed disputes,
BioGatekeeper Inc. v. Kyoto University
and Consumer Watchdog v. WARF, illustrate the possibilities—and limits—of this
legal development in stem cell patenting.
In this Forum, we explore the past state
of affairs in stem cell patents, the changes
wrought by the AIA (as illustrated by the
BioGatekeeper and Consumer Watchdog
suits), and the likely future for the security
of stem cell patents.
Patent Challenges at the PTO
before the AIA
Procedurally, patent disputes typically
proceed along one of two paths. The first
uses the federal court system to challenge
the validity of issued patents. As a matter

of constitutional law, all federal court
cases must possess an ‘‘actual case or
controversy:’’ ‘‘that the dispute be ‘definite and concrete, touching the legal relations of parties having adverse legal interests’’’ (MedImmune, Inc. v. Genentech,
Inc., 2007). Practically, this means either
that the patent holder would first sue an
accused infringer directly or that the patent holder would threaten the infringer
with a suit such that, for legal purposes,
there exists a ‘‘substantial controversy’’
between the parties. The corollary to this
maxim, however, is that outsiders who
do not live under the threat of being
sued have no right to challenge the
validity of the patent in federal court.
Thus, at least prior to the AIA, challenging the validity of a patent or patent
application in federal court was generally
limited to those who had a direct, legal interest in the patent: inventors who had
been wrongfully left off of the patent application, competitors who had pending
patent applications, licensees of the
patented technology, or users who had
been sued for infringement (Plomer
et al., 2008).
The second pathway involves the PTO.
Prior to the AIA, several administrative
procedures allowed a variety of parties
to request that the PTO reconsider patents already issued by the agency. One
such procedure, ‘‘inter partes reexamination’’—available since 1999—allowed
any person, at any time, to petition the
PTO to reconsider the patent in light of
new scientific or technical references
that cast doubt on the patent’s validity
(Tindell, 2007). At the same time, the
petitioner was limited to challenging the
patent’s validity on those references—
and not for other technical defects in
the patent document. In response, the
patent holder could alter its patent’s

claims at any time to avoid—or delay—
further proceedings. Usually, inter partes
reexamination functioned as a dispute
resolution mechanism for parties with a
direct interest in a particular patent:
over 75% of all inter partes reexamination requests ever filed concerned patents concurrently being litigated by the
same parties in federal court. Furthermore, relative to the pace of federal
litigation, disputes tended to drag on,
taking 3 years, on average, for the PTO
to decide a reexamination proceeding
(Love and Ambwani, 2014).
These limits on challenging patents,
combined with a robust licensing market,
led stem cell patents to be infrequently
challenged prior to the AIA (Roberts
et al., 2014). The few challenges that did
occur mostly concerned University of
Wisconsin professor James Thomson’s
broad, pioneering human embryonic
stem cell (hESC) patents (Plomer et al.,
2008). There, several prominent scientists objected to the Wisconsin Alumni
Research Foundation’s (WARF’s) aggressive licensing and enforcement strategies. These scientists joined the legal
advocacy group The Foundation for
Taxpayer and Consumer Rights (now
called Consumer Watchdog) to challenge
James Thomson’s foundational human
embryonic stem cell patents before the
PTO. Nonetheless, such challenges remained rare. The torpid pace of the inter
partes reexaminations further discouraged stem cell inventors from petitioning
the PTO to challenge their competitors’
patents; advances in the field would likely
eclipse the patented technology before
the PTO completed its proceedings
(Iancu and Haber, 2012). Therefore,
stem-cell-related patents remained relatively safe from challenges until the passage of the AIA.
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Patent Challenges after the AIA
The AIA may have changed things dramatically. Although it left the requirements for
federal litigation largely intact, the Act
substantially altered the administrative
procedures available to the public to
challenge patents at the PTO. First, and
foremost, the AIA revamped the old
system of inter partes reexamination into
a new system of inter partes review.
Rather than utilizing an ‘‘amendment and
response’’ procedure that accounted for
much of the old system’s delay, the new
system proceeds in a quick, trial-type
fashion that gives the PTO authority to
cancel all of a patent’s claims in their
entirety. In addition, multiple parties—
including members of the public with no
legal interest in the patent—may join in
the action at the discretion of the PTO.
And, while the filing fee for instituting an inter partes review is high—to date, at least
$27,500—attorneys’ fees for inter partes
reviews often cost less than one-tenth
of traditional, federal court patent litigation
(http://www.mintz.com/newsletter/2014/
Advisories/4363-1014-NAT-IP/). The proceedings also take half the time, roughly
15 months from start to finish. Inter partes
reviews are also legally easy to initiate
and, so far, have been very successful, invalidating over 70% of the patent claims
adjudicated at the PTO (Love and Ambwani, 2014).
In addition, anyone may now challenge
patents currently before the PTO in what
are known as ‘‘preissuance submissions.’’ Like the prior system of inter
partes reexamination, preissuance submissions allow a third party to submit prior
published technical literature useful in
assessing—or challenging—the validity
of the contested patent, along with a
concise description of how the submitted
references cast doubt on the patent as
written. In contrast to the fee for inter
partes reviews, the fees for preissuance
submissions are quite cheap: several
hundred dollars, depending on the number of references included by the challenger (Iancu and Haber, 2012). Several
other administrative challenges have
also been created by the AIA—such as
covered business method reviews—but
it is unlikely that they will greatly affect
stem cell patents.
In any event, the AIA’s new administrative procedures have been successful
insofar as they have allowed greater,

faster participation by expanding the
criteria for filing trial-type challenges
beyond those who are directly threatened by enforcement. So far, more inter
partes reviews have been filed since the
AIA took effect in 2012 than all of the inter partes reexaminations from 1999–
2012. The PTO now also receives, on
average, roughly 70 preissuance submissions each month (http://www.law360.
com/articles/581512/trends-from-2-yearsof-aia-post-grant-proceedings). These
numbers appear likely to increase as
practitioners become comfortable with
the new procedures.
The Consumer Watchdog and
BioGatekeeper Challenges
The ease and popularity of administrative
patent challenges after the AIA have
affected some of the more prominent
stem cell technologies. After Consumer
Watchdog lost its challenge to WARF’s
stem cell patents before the PTO, the organization appealed the decision to federal court. There, it asked the U.S. Court
of Appeals for the Federal Circuit to apply
the U.S. Supreme Court’s recent decision
on gene patenting, Association for Molecular Pathology v. Myriad Genetics, Inc. In
Myriad, a unanimous Supreme Court
held that ‘‘naturally occurring’’ DNA segments were not patent eligible, even
though they had been ‘‘isolated’’ from
the surrounding chromosome (Kesselheim et al., 2013). Consumer Watchdog
argued that WARF’s patents claimed
that stem cells were analogous to the isolated DNA segments in Myriad because
their properties are found in all embryonic
stem cells, including their naturally existing counterparts.
But, in its June 2014 decision, the Federal Circuit did not address the substance
of Consumer Watchdog’s challenge.
Rather, it held that because all federal
court challenges of patents—even those
stemming from the freely open, inter
partes review process—required an
‘‘actual case or controversy,’’ Consumer
Watchdog did not have standing to appeal the PTO’s decision. Because WARF
never sued or threatened to sue Consumer Watchdog itself, the group had no
standing to appeal the PTO’s decision; it
had suffered no legally apparent injury
related to the patent.
Not to be deterred, the group took
its fight to the Supreme Court. In its
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petition last October, it argued that it
should not have to meet the typical
standing requirements to bring a case
in federal court because the AIA
expressly gives it, and other third parties,
the right to appeal the PTO’s decision.
Despite these arguments, the Supreme
Court announced this February that it
was declining to revisit the Federal Circuit’s decision.
Consumer Watchdog’s aggressiveness teaches an important lesson about
the future of patent challenges on
controversial technologies like stem
cells. At first glance, Consumer Watchdog’s fight against a patent that expires
in 2015 would seem puzzling. The scientist-licensees that were named on the
original reexamination challenges dropped off the case before the PTO’s 2012
decision. These individuals, whether
motivated by money or by an appeal to
public fairness, were either satisfied
that the reexaminations did the work of
limiting Thomson’s claims, settled with
WARF privately, or simply felt it was
time to move on. That left Consumer
Watchdog with no real financial dog in
the fight, other than an appeal to public
policy.
But the concern with public access
to promising technologies may motivate
future attorneys to take up mantles
against more stem cell patents, collaborating with publicly minded researchers
as petitioners, just as with the Myriad
case. In this way, the future of patent
challenges may increasingly be at the
hands of special interest, anti-patent
groups and scientists, rather than
spurned licensees.
Not all new stem cell patent disputes
are so public-minded, however. As in
the early days of the WARF challenge,
the BioGatekeeper case appears to
have those with financial interests challenging induced pluripotent stem cell
(iPSC) patents. Currently an unknown
entity, BioGatekeeper, Inc. filed an inter
partes review against one of Nobel Prize
winner Shinya Yamanaka’s foundational
iPSC patents. Like the Consumer
Watchdog challenge, the BioGatekeeper
challenge invokes obviousness: that the
cellular reprogramming discovery was
based on pre-existing art, publications,
and patents that predate the Yamanaka
filings (Simon et al., 2010). In this case,
the prior art belongs to Rudolf Jaenisch,
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the inventor and his employer, the Whitehead Institute.
Although the PTO ultimately declined
to institute BioGatekeeper’s challenge,
the case stands as an example of how
patent challenges become easier—
and cheaper—to initiate after the passage of the AIA. There appear to be
multiple motivations driving the low
threshold use of the AIA. Analysts estimate that total global revenues for companies that supply iPSC research products will exceed $1 billion by 2015
(BioInformant Worldwide, 2014). The first
clinical study involving the transplantation of iPSCs into humans began recruiting patients in August 2013. This
safety study will use iPSC-derived retinal
pigment epithelium to restore vision in
patients with wet age-related macular
degeneration, possibly addressing a
large unmet medical need. The spoils
of the market are being fought for among
a highly fragmented group of dozens
of patent holders, a third of which are
corporate affiliated (Roberts et al.,
2014). Thus, the AIA may provide
a way for hungry market entrants to
challenge patents on older, foundational
research without the standing requirements present in the Consumer
Watchdog suit.
The Future of Stem Cell Patents
after the AIA
As the Consumer Watchdog and BioGatekeeper challenges illustrate, the AIA
has provided broader avenues for third
parties to challenge stem cell patents
before the PTO. Although these procedures still possess limits, these cases do
not appear to be isolated incidents.
Rather, three facets of stem-cell-related
patents in particular suggest that such exchanges are likely to become more
frequent in the future.
First, there is good reason to believe
that the robust licensing market that
generated such peace among stem
cell patent holders will not last forever.
A recent study suggests that the
biggest threat to the commercialization
of iPSCs is ‘‘the potential formation of
a patent thicket and mismanaged
licensing practices in a field that has
begun to privatize at an early preclinical
phase’’ (Roberts et al., 2014). Given
the rapid transfer of stem-cell patents
from the public to the private sector,

this threat is quite real. As such, the
AIA seems to encourage commercial enterprises and inventors to file patent
challenges early and often to stave off
future competition or gain entry to the
market.
Second, as stem cell biotech companies grow and become publicly traded,
they increasingly become attractive targets for hedge funds seeking to take short
positions. The AIA’s new procedures
allow short investors—as ‘‘non-interested
parties’’—to simultaneously challenge
their target’s patents at the PTO while taking a short equity position in the hopes
of either profiting on the challenge’s
downturn or receiving a settlement payment. Indeed, this is precisely the strategy
recently implemented by Dallas-based
Hayman Capital in the pharmaceutical
context. In February 2015, Hayman
Capital filed its first inter partes challenge, against Acorda Therapeutics’
patent on Ampyra, a multiple sclerosis
drug (http://www.reuters.com/article/2015/
01/07/pharmaceuticals-haymancapitalidUSL3N0UM42O20150107). As of April
2015, it has filed four more challenges. To
the extent Hayman is successful, it
may cause other stem-cell IP investors,
like BioGatekeeper, to file additional
challenges.
Lastly, the new system of inter partes
review allows competing inventors and
frustrated researchers a fast and cheap
way to challenge patents—or to demand
royalty-free licensing or academic credit.
In addition, given the fractious history of
stem cell research, groups that object to
patenting on moral grounds—such as opposition to patenting forms of life—could
deploy the AIA as a low-cost way to delay
or derail the commercialization of new
discoveries. Given the heated and very
public priority disputes simmering in the
stem cell field, this may remain more
than a distant possibility in some extreme
cases.
Whether the availability of new avenues to challenge patents means solutions or problems to stem cell patenting
depends on the reader’s point of view as
to the propriety of stem cell patents
in the first instance. As problems, the
answer to fixing them lies in maintaining the robust licensing market that
currently exists for many stem cell patents. As long as licensable patents are
affordable, competitors will likely pay

for certainty rather than a roll of the
dice at the PTO. As solutions, time
will tell whether the AIA ultimately has
its intended effect of making it cheaper
and easier to weed out bad patents
before they wend their way into federal
court.
Conclusions
Stem-cell-related patents have enjoyed
a relatively stable existence since they
began to be issued in the early 1990s.
Much of that can be attributed to the
robust licensing market for the underlying
technologies and because few legal avenues existed for third parties to cheaply
and effectively challenge overbroad or
invalid stem cell patents. The AIA and
the commercial development of new
stem cell technologies may upset this balance. Although still constrained by
limits—as demonstrated by the Consumer Watchdog and BioGatekeeper
cases—new administrative procedures
before the PTO make it substantially
easier (and cheaper) to challenge stem
cell patents as they become issued. This
may be a natural stage in the life cycle of
any rapidly developing area of law and
technology.
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